Valuation dashboard for NeoGenomics, Inc. (NEO) with P/E N/A, P/B 0.66, EV/EBITDA 58.16 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers.
Analysis Summary
NeoGenomics, Inc. reported revenue of $727.3M in the most recent fiscal year, growing at a 5-year CAGR of 10.4%.
Trailing-twelve-month margins: gross margin 42.9%, operating margin -8.6%, net margin -6.8%.
At the current price of $19.59, NEO has negative trailing earnings (P/E not meaningful) and an ROE of -6.31%. Market capitalisation stands at $503M.
Balance sheet quality for NEO: current ratio of 4.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.66 |
| EV / EBITDA | 58.16 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-76.95 |
| vs Current Price | -492.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NEO | NeoGenomics, Inc. | $511M | 0.66 | -6.3% | |
| 0R0H.L | Thermo Fisher Scientific Inc. | $244.6B | 35.47 | 4.45 | 12.6% |
| TMO | Thermo Fisher Scientific Inc. | $241.0B | 35.36 | 4.64 | 13.4% |
| 0R2B.L | Danaher Corporation | $150.1B | |||
| DHR | Danaher Corporation | $149.3B | 39.34 | 2.98 | 7.7% |
| NTRA | Natera, Inc. | $52.5B | 30.51 | -11.7% | |
| 0HAV.L | Agilent Technologies, Inc. | $47.8B | 95.79 | 6.15 | 6.4% |
| 0JDM.L | IQVIA Holdings Inc. | $45.7B |
Price
| Price | $19.59 |
| Market Cap | $503M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -6.31% |
| Return on Invested Capital | -5.03% |
| Return on Assets | -3.84% |
| Gross Margin | 42.92% |
| Operating Margin | -8.63% |
| Net Margin | -6.77% |
Related companies: ACRS · ARCT · HUMA · MDXH · QTRX · SGMT · SMTI
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NEO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks